Premier Perspectives The blog for insider insights in clinical development Clinical Research: Phase 1 - Phase 4 In Silico Modeling Unveils a New Era in Rare Disease Drug Development By Abie Ekangaki May 4, 2023 Featured Posts Clinical ResearchPhase 1 - Phase 4 To Placebo or Not to Placebo? The Great Debate in Rare Disease Trials By Abie Ekangaki March 31, 2023 Clinical ResearchPhase 1 - Phase 4 9 Tips for Designing and Operationalizing Early-Stage Precision Oncology Studies By Abie Ekangaki February 2, 2023 Recent Posts By expertise area All expertise areas Medical DeviceRare DiseaseOncology & HematologyDiagnosticsDigital TherapeuticsMedTechPediatricsNeuroscienceAnalgesiaDermatologyOtherCOVID-19Cell & Gene TherapyWomen's HealthReal-World & Late PhaseCareers By functional area All functional areas Development StrategyClinical Research: Phase 1 - Phase 4ConsultingData Management & BiostatisticsFunctional Service Provider (FSP)Global ComplianceMedical and Regulatory AffairsPatient and Stakeholder EngagementProject ManagementQualityReal-World Science and Late PhaseSafety/PharmacovigilanceStudy DesignStudy Start-UpOtherCOVID-19Product Development Clinical ResearchPhase 1 - Phase 4 Can Your Protocol Flex? The Importance of Adaptive Trial Designs in Precision Oncology Studies By Abie Ekangaki January 30, 2023 Clinical ResearchPhase 1 - Phase 4 5 Key Takeaways: Insights on Alternative Designs to the Traditional 3+3 Design in Phase 1 Dose Escalation Studies By Abie Ekangaki April 8, 2021 Clinical ResearchPhase 1 - Phase 4 Considerations for Applying Adaptive Design Approaches to Early Oncology Studies By Abie Ekangaki August 20, 2020 Clinical ResearchPhase 1 - Phase 4 Minimizing Early-Stage Oncology Failures with Adaptive Design Approaches By Abie Ekangaki August 5, 2020 COVID-19 Statistical Considerations for FDA COVID-19 Guidance By Abie Ekangaki March 27, 2020 Clinical ResearchPhase 1 - Phase 4 Leadership Development and Becoming a More Effective Change-maker By Abie Ekangaki April 26, 2019 1 2 Next × ALSO OF INTERESTPremier Research Vice President, Statistical...Key Considerations When Designing a Phase 1...7 Questions About Clinical Evaluations for MDR
